D and D Pharmatech Announces Initial Clinical Results for Astatine-211 Prostate Cancer Therapy
"Tumor-Targeting Profile Confirmed"
Study Results Published in International Journal "EJNMMI"
D and D Pharmatech announced on February 19 that the first clinical results for [211At]YF2, a next-generation alpha radiotherapeutic for the treatment of prostate cancer based on astatine-211 and currently being developed by its U.S. affiliate G Alpha, have been published in the international journal European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI).
This clinical study was designed to evaluate the biodistribution, radiation dosimetry, and safety of [211At]YF2 in patients with metastatic castration-resistant prostate cancer (mCRPC). According to D and D Pharmatech, [211At]YF2 demonstrated its potential as a next-generation radiopharmaceutical by clearly targeting metastatic lesions, which are a major cause of cancer-related death, while minimizing damage to normal organs. Based on these initial clinical results, G Alpha is preparing subsequent clinical trials of ZA-001, a next-generation candidate with an improved formulation.
ZA-001 is a next-generation alpha radiotherapeutic that targets prostate-specific membrane antigen (PSMA) and selectively kills cancer cells by emitting potent, astatine-211-based high-energy alpha particles. Unlike existing alpha radioisotopes such as actinium-225 or lead-212, astatine-211 emits only high-energy alpha particles without beta particle emission during radioactive decay. It also has a short half-life of approximately 7.2 hours, which allows strong radiation effects within the tumor while reducing residence time in the body, thereby minimizing damage to normal tissues.
The main limitation of currently approved PSMA-targeted radiotherapeutics and alpha therapies under clinical development based on actinium-225 and lead-212 is that, in addition to cancer cells, they show high accumulation and radiation emission in normal organs where PSMA is expressed, particularly the salivary glands, leading to severe organ damage and adverse effects. As a result, there has been a consistent call for the development of next-generation PSMA-targeted therapies that act selectively on cancer cells while minimizing accumulation in normal organs.
Astatine-211 emits X-rays along with alpha particles, enabling SPECT/CT imaging and allowing in vivo drug distribution to be assessed without additional contrast agents.
In SPECT/CT analysis, [211At]YF2 was observed to accumulate in metastatic lesions within one hour after administration. Accumulation in the salivary glands was up to ten times lower than that of existing therapies under development. No grade 3 or higher severe adverse events were reported in participating patients.
This clinical study was designed as a microdosing trial to evaluate the biodistribution and safety of the drug in the body. It is significant in that it provided foundational data for designing future dose-escalation clinical trials.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Lee Seulgi, CEO of D and D Pharmatech, said, "These initial clinical results demonstrate that the characteristics observed in preclinical models, namely the minimization of radiation absorption in normal organs and the selective targeting of cancer cells, are reproduced in patients with prostate cancer," adding, "We have secured important evidence that ZA-001, for which subsequent clinical development is planned, can be developed as a next-generation precision radiotherapeutic."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.